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Abstract  
Malignant mesothelioma (MM) is an aggressive cancer associated with asbestos exposure. Studies 
of familial malignant pleural mesothelioma (MPM) have suggested the existence of a genetic 
predisposition. Information on the role of genetic risk factors in the development of MM has been 
growing in the last years, and both low- and high-risk genetic factors have been identified, but none 
has ever been shown to induce MM in the absence of asbestos exposure. 
Low-risk genetic factors have been identified in studies that systematically analyzed the whole 
genome. These low-risk factors alone carry a relative risk of MPM that is 10- to 15-fold lower than 
that carried by asbestos exposure; however, a large number of these factors in combination may 
increase the impact of asbestos exposure. 
High-risk factors are truncating variants in BAP1 and other genes belonging to DNA repair 
pathways. Heterozygous germline variants in these tumor suppressor genes may favor 
carcinogenesis after the occurrence of a second somatic variant that impairs the wild-type allele, 
causing genetic instability, due to the suppression of a specific DNA repair pathway, and 
transformation. 
This genetic predisposition may have translational consequences, as it may predict patient response 
to drugs that induce tumor-specific synthetic lethality. 
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Abbreviations 
MM, malignant mesothelioma; MPM, malignant pleural mesothelioma; RR, relative risk; NGS, 
next generation sequencing; SNPs, single nucleotide polymorphisms; BER, base excision repair; 
GWAS, genome-wide association study; OR, odds ratios; BAP1-TPDS, BAP1-Tumor 
Predisposition Syndrome; MBAITs, Melanocytic BAP1-mutated atypical intradermal tumors; 
NSCLC, non-small cell lung cancer; HRR, homologous recombination repair; HBOC, hereditary 
breast ovarian cancer syndrome; XP, xeroderma pigmentosum; NER, nucleotide excision repair; 
MMR, Mismatch DNA Repair; HNPCC, hereditary nonpolyposis colorectal cancer; alt-NHEJ, 
alternative non-homologous end-joining; NHEJ, non-homologous end-joining; SSB, single strand 
break;  DSB, double strand break; FA, Fanconi Anemia; PTV, pathogenic truncating variant, 
PARPi, PARP inhibitor. 
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1. Introduction 
MM is an aggressive tumor that affects the lining membrane of the serous cavities of the body, 
including the pleura, peritoneum, pericardium, and the vaginal tunic of the testicles; the most 
common is MPM. Most cases of MPM are due to exposure to asbestos, or other fibrous minerals, 
such as erionite, fluoro-edenite, winchite and richterite [1,2]. 
A very limited proportion of MPM estimated in Italy in the range from 1.7% to 4.7% is caused 
by exposure to ionizing radiation for diagnostic or therapeutic purpose [3,4]. Current estimates of 
the incidence of MM show large variations among the different countries, with the highest 
incidence rates (Age standardized rates over 30/million) observed in cancer registries from Great 
Britain, Australia, Germany, Italy and other industrialized countries [5,6]. Recent data show that 
despite the main risk factor being identified, the reduction in the use of asbestos and considerable 
efforts made to clear asbestos from the environment starting in some countries since the early 
1980s, the incidence of the disease so far has failed to decline because of the extremely long 
latency. However the first signs of a reduction of incidence are being observed [7]. 
Asbestos has been widely used for decades all over the world. Indeed, it is very difficult to prove 
that an individual has never been exposed to asbestos [8]. A direct correlation has been shown 
between the amount of asbestos exposure, the latency and the risk of MPM [8] Nevertheless, only 
10-17% of individuals highly exposed to asbestos develop MPM [9]. This observation has led to the 
hypothesis of an individual response that modifies the effect of asbestos exposure. The possible role 
of genetic risk factors was also supported by the description of families with several genetically 
related cases, including MM and other neoplasms [10]. An early description of familial 
aggregations of MPM reported a high incidence of mesothelioma in two villages of Cappadocia, 
whose buildings were built using material from erionite-rich boulders [11,12]. Several clusters have 
also been described in Italy [13–15]. Such familial aggregation may be due to co-exposure to 
asbestos, as in the case of “conjugal MPM”, which is attributed to women handling and washing the 
work clothes of spouses exposed to asbestos at work [14,16]. 
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In the case of MPM, a genetic risk factor is defined as a DNA variant that can modify the effect 
of asbestos exposure on the risk of MPM. Classically, genetic factors are divided into three types 
based on their RR: low-risk (RR<1.5), moderate-risk (RR 1.5-5) and high-risk (RR>5) factors. 
The aim of our study was to conduct a literature review on genetic risk factors predisposing to 
MM, discussing separately those conferring a low risk and those conferring a moderate/high risk. 
The literature search was carried out in the NCBI Pubmed database using the keywords “BAP1 
germline mutations/variants and mesothelioma”, “genetic risk factors predisposing to 
mesothelioma”, “germline mutations predisposing to mesothelioma”. 
 
2. Low risk genetic factors  
Low-risk genetic factors are those involved in multifactorial diseases, also called complex diseases 
[17]. They are DNA variants that show a statistically significant association with the disease in 
case-control studies. Sometimes the variant can modify the function of a gene in different ways; 
other times the variant is simply located close to the real pathogenic variant and co-inherited. 
In the pre-genomic era, i.e. before the mapping and sequencing of the human genome and the 
general diffusion of the NGS technique, studies on low-risk genetic factors that could predispose an 
individual to MPM used a candidate gene approach driven by a biological hypothesis [18–20]. In 
particular, the observation that patients with inherited defects in DNA repair genes were susceptible 
to a constellation of tumors, and the identification of reduced DNA repair activity in the 
lymphocytes of patients with cancer, suggested that DNA repair genes might play a role in one’s 
predisposition to MM [15]. Thus, SNPs in several DNA repair genes were studied in the germline 
genome of MPM patients, but resultant associations were inconsistent, probably due to the small 
number of MPM patients and controls analyzed. An interesting association was observed between 
MPM and a missense variant in XRCC1, a gene encoding for a protein involved in the BER 
pathway that repairs single-strand breaks due to reactive oxygen species [20]. The BER pathway is 
directly involved in the repair of genetic lesions due to asbestos fibers. A detailed review of 
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association studies on genetic SNPs in MPM was previously published [19].  Because of the low 
RR, studies must have large panels of MPM patients and controls if they are to detect these risk 
factors. These are often GWAS, in which thousands of variants are simultaneously screened to 
identify those that are differently represented in MPM patients and controls. To obtain large sample 
sizes, international collaborations are needed, especially when dealing with rare diseases like MPM. 
To-date, two GWAS on MPM have been performed: one in the Italian and one in the Australian 
population [23,24]. The Italian GWAS carried out by our research group included 407 MPM 
patients and 389 controls from Casale Monferrato, Genoa, and Turin. The Australian GWAS 
included 428 MPM patients and 778 controls. Each study carefully evaluated asbestos exposure in 
both groups and used the other for validation. The two studies identified different SNPs associated 
with MPM status (Table 1a and 1b; Figure 1A), with ORs ranging from 0.54 to 2.37. Each variant 
alone carries a very low risk, which is 10- to 15-fold lower than that carried by asbestos exposure 
[8], but interaction was observed between asbestos exposure and several of the SNPs identified in 
our Italian GWAS and the same study also suggested the joined contribution of different SNPs to 
the interaction [25]. This interaction analysis was conducted with both additive and multiplicative 
models, since we did not have experimental or theoretical reasons to choose either. Additive 
interaction is present when the joint effect of the two risk factors is different from the sum of the 
individual effects, whereas multiplicative interaction is present when the joint effects of the two risk 
factors differ from the product of the individual effects [26]. We found that six SNPs (rs1508805, 
rs2501618, rs4701085, rs4290865, rs10519201, rs763271) deviated from the additive model; 
interestingly, four of them (rs1508805, rs2501618, rs4701085, rs10519201) also deviated from the 
multiplicative model. This supports their role in modulating the effects of asbestos exposure. 
Moreover, rs7632718 is localized within SLC7A14, a gene located in a region that has been found to 
be frequently duplicated in the genome of MPM patients [27]. It is noteworthy that an interaction, 
although not statistically significant, was also found for rs73034881, which is localized in a region 
that encompasses FOXK1. This gene is a suggestive risk factor because it encodes for a 
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transcription factor that physically interacts with BAP1 (Figure 1B), the first high-risk genetic 
factor for MPM. FOXK1 is located in a region that was identified as associated to MPM both in the 
Italian and the Australian GWAS [23,24] and was found hypomethylated in MPM tissues [28] 
(Figure 1B).  
 
3. High and moderate risk genetic factors 
The most studied genetic factor carrying a high risk is BAP1. Other genes carrying a high or 
moderate risk are reported in Table 2 and Figure 2A. 
3.1 BAP1-tumor predisposition syndrome  
Germline variants in BAP1 characterize BAP1-TPDS (MIM#614327), which is an autosomal 
dominant disease (i.e. each patient is heterozygous for a germline pathogenic mutation) [29,30]. 
Individuals with BAP1-TPDS have a high risk of developing a constellation of tumors, including 
mesothelioma, cutaneous and uveal melanoma, clear cell renal carcinoma, and basal cell carcinoma 
(Table 2). Moreover, they develop peculiar skin tumors, called atypical Spitz tumors or MBAIT, 
which may lead to a diagnosis of BAP1-TPDS [31]. Patients with uveal melanoma and germline 
variants in BAP1 have a bad prognosis [29,32], whereas patients with mesothelioma and germline 
variants in BAP1 seem to have a longer survival than those without these variants [33–35]. So far, 
only 182 families with BAP1-TPDS have been identified, but the penetrance of the defect has not 
yet been calculated [30–33,35–50]. On the other hand, it is well known that these patients may 
develop more than one tumor. 
Mesothelioma is the second most frequently reported cancer in patient with BAP1–TPDS after 
uveal melanoma [29,40]. So far, 77 families with this tumor have been reported [39,50]. Age at 
onset of MPM in patients with BAP1-TPDS is overall earlier than that in patients without this 
syndrome, but as observed in environmentally exposed patients, compared to occupationally 
exposed patients [33,35]. Most patients with BAP1–TPDS develop MPM, but peritoneal 
mesothelioma has also been reported [27,28,30]. Interestingly, peritoneal mesothelioma has been 
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identified more frequently in women with a germline variant in BAP1 compared to the general 
population, in which peritoneal mesothelioma is more likely to occur in men [40]. 
The prevalence of BAP1-TPDS among patients with familial MPM varies between 6% and 7.7% 
[28,31], which is higher than the prevalence observed in sporadic cases (<1%) [27,32,33]. Other 
tumors that have been reported in patients with BAP1–TPDS include breast cancer [23,25,34,35], 
cholangiocarcinoma [25,35,36], meningioma [43–46], neuroendocrine tumors [37,40], NSCLC 
[32,44,47,48], thyroid carcinoma [41,49], and mucoepidermoid carcinoma of the tongue [34] and 
others. Larger numbers of BAP1 mutation carriers should be studied to exclude a coincidental 
association. 
 
3.2 The BRCA1 associated protein-1 (BAP1) 
BAP1 (#MIM 603089) is located on 3p21.1 and encodes for a tumor suppressor gene that is 
frequently mutated in cancer genomes, including mesothelioma [53]. Its protein is a ubiquitin 
carboxy-terminal hydrolase, a nuclear deubiquitinating enzyme, that catalyzes the cleavage of an 
ubiquitin residue from several proteins. BAP1 has 729 amino acids and plays an important role in 
chromatin modulation, transcriptional regulation, cell proliferation, DNA repair, cell death, and 
glucidic metabolism [54–58]. The BAP1 protein is part of a multiprotein complex that includes 
FOXK1, HCFC1, ASXL1/2, and OGT [59], and it interacts with BARD1. BAP1 has a ubiquitin C-
terminal hydrolase domain, and two nuclear localization sequences. 
Bap1
+/-
 mice show increased sensitivity to asbestos compared with wild-type mice, because they 
develop MPM when exposed to low amounts of asbestos [60,61]. This may be true also for humans, 
but quantification of asbestos exposure was reported only for ten subjects with BAP1–TPDS 
[39,62].  Moreover, environmental exposure to carcinogenic mineral fibres is generally involuntary 
and unknown [63,64]. 
Follow-up data on BAP1–TPDS carriers are also lacking. It is possible that the developed tumor 
type depends on the carcinogen to which patients are exposed. For example, one individual with 
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BAP1-TPDS, who was not exposed to either domestic or occupational asbestos, died from 
mucoepidermoid carcinoma of the base of the tongue, whereas his mother, his maternal aunt, and 
his grandmother who were exposed to domestic asbestos developed MPM [34]. 
Germline variants are often truncating and generally private, only ten have been identified in 
more than one patient within apparently non-consanguineous families [40]. Recurrent variants could 
be due to mutable hot spots within the gene or to the existence of an unknown consanguinity among 
the families. An example is the case of four American families that shared a common German 
ancestor nine generation earlier [65]. Moreover, the tumor suppressor gene BAP1 is frequently 
deleted in the genome of many tumors, including mesothelioma, as observed in 
immunohistochemical studies [66]. In the case of tumors that arise in patients with germline 
variants in BAP1, all these patients’ cells harbored a single wild-type allele. Further somatic 
variants affect the wild-type allele, leading to the loss of tumor suppressor function and 
carcinogenesis. Somatic variants are of different types and include PTVs, large deletions, or 
chromosomal loss [39,53,67,68] 
 
3.3 Other cancer syndromes that predispose to MPM 
Besides BAP1, eleven other genes have been identified as involved in predisposition to MPM, i.e. 
CDKN2A, PALB2, BRCA1, FANCI, ATM, SLX4, BRCA2, FANCC, FANCF, PMS1, XPC. Except 
for CDKN2A, which is involved in proliferation control, all these genes have a role in DNA repair, 
most of them in the HRR pathway. Germline variants in these genes are responsible for several 
cancer syndromes (Table 2), and each syndrome leads to a predisposition to specific tumor types 
with a high or moderate risk, depending on the gene and the tumor. For example, BRCA1, BRCA2, 
and PALB2 can predispose women to breast and ovarian cancers. BRCA1 and BRCA2 are the first 
genes identified as high-risk factors in the development of HBOC, and they are also its most 
frequent cause. They are tumor suppressor genes, whose inactivation, due to a somatic variant 
generated on the wild type allele, induces carcinogenesis in the target tissues of women with a 
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germline variant. BRCA1 and BRCA2 can also predispose to prostate and pancreatic carcinomas 
[69]. 
Homozygous germline variants in BRCA1 and BRCA2 (also called FANCS and FANCD1, 
respectively) are responsible for Fanconi anemia, an autosomal recessive disorder characterized by 
genetic heterogeneity. This disorder can be caused by at least twenty different genes [70], all of 
which encode proteins that act in a signaling pathway involved in the response to crosslinking 
agents. The first step of this pathway is the formation of a multiprotein complex, which includes 
proteins A, B, C, E, F, G, L, and M, and which has the function of ubiquitin ligase. When the DNA 
is damaged, the complex interacts with the FANCD2 and FANCI proteins, which are consequently 
monoubiquitinated and translocated to nuclear foci where they have a role in HRR, in coordination 
with other proteins, including BRCA1 (FANCS), BRCA2 (FANCD1), PALB2 (FANCN), and 
BRIP1 (FANCJ). Germline variants have been found in seven FA genes in patients with MPM, i.e. 
BRCA1, BRCA2, PALB2 (FANCN), FANCC, FANCF, FANCI, and SLX4 (FANCP).  
XPC is one of the eight genes responsible for XP (MIM# 278720) and is involved in the NER 
pathway, a DNA repair system that removes the pyrimidine dimers induced by exposure to 
ultraviolet radiation. Patients with XP are hypersensitive to ultraviolet radiation and are susceptible 
to basal cell carcinoma, squamous cell carcinoma, and melanoma [71]. PMS1 has a role in the 
MMR pathway, and several genes involved in this pathway predispose to HNPCC or Lynch 
syndrome [72,73]. Finally, CDKN2A plays an important role in cell cycle regulation [74]. Germline 
variants in this gene predispose to melanoma and pancreatic cancer. It is also interesting to note that 
anecdotal studies had previously reported MPM in patients with Li-Fraumeni syndrome or 
neurofibromatosis Type 2, due to germline variants in TP53 or NF2 respectively [75,76]. Some of 
these genes are often somatically mutated or lost in MPM, e.g. BAP1, CDKN2A, NF2, TP53, 
whereas BRCA2  loss was reported in a single study [53,67,68,77] 
The involvement of many DNA repair genes is in line with the important role of BAP1 as a 
driver gene in MPM, but it is also in accordance with two (or 3 carbone?) recent independent 
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studies. The first showed that 12% of 500 patients with different types of metastatic tumors carried 
germline pathogenic variants, 75% of which are in DNA repair genes [78]. This study shows that 
our results on MM patients are part of a more general predisposition that includes many metastatic 
tumor types. The second study reported that 12% of 198 MM patients carried germline mutations in 
cancer-susceptibility genes, 83% of which were in genes involved in DNA damage sensing and 
repair genes and 50% in HHR genes [62] (Figure 2). This paper also reports that germline mutations 
are more common in peritoneal compared with pleural MM [62]. 
 Overall, the observation of a substantial proportion of MM patients carrying germline 
mutations in DNA repair genes was made in two or three consonant papers, that included 298 
patients [79,62,78]. Finally, it is interesting to observe that the patients who carried PTVs in these 
cancer predisposing genes (i.e. CDKN2A, PALB2, BRCA1, FANCI, ATM, SLX4, BRCA2, FANCC, 
FANCF, PMS1, XPC and BAP1) were exposed to a lower amount of asbestos as compared to 
patients who did not carry such variants. The difference is statistically significant [39,79] and this 
observation was confirmed by Panou et al. [62]. Overall, these data suggest that these patients are 
more sensitive to asbestos exposure. 
 
4. Translational consequences 
Although the identification of low risk factors has no clinical relevance so far for their carriers, the 
translational consequences of being a carrier of a mutation in a HHR repair gene are potentially 
relevant. 
It is well known that patients with ovarian cancer and germline variants in BRCA1 or BRCA2 
respond to PARPi drugs, through a mechanism called synthetic lethality [80,81], a type of genetic 
interaction characterized by two (or more) defects that are not lethal singularly but are lethal when 
both are present in a cell [82]. PARP1 is a nuclear enzyme that plays key role in SSBs, BER, and 
alt-NHEJ [83]. PARP1 binds to SSBs and initiates the PARylation of its substrate proteins, 
resulting in the formation of polymers of ADP-ribose (PAR). PAR synthesis is required for the 
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recruitment of SSBs repair scaffolding proteins. PARP1 autoPARylation induces the release of 
PARP1 from DNA and its inactivation [82]. Treatment with some PARPi (e.g. rucaparib, olaparib, 
niraparib, and talazoparib) traps PARP1 to the site of DNA damage, interfering with the progression 
of replication fork. This PARP inhibition causes the accumulation of SSBs that evolve to DSBs 
through replication fork collapse. HRR and NHEJ are the main pathways used to repair DSBs and 
restart replication forks stalled by PARPi. If HRR is deficient due to loss of tumor suppressor 
genes, the damage could also be repaired by alt-NHEJ that is not functional, because it requires 
PARP1. In the absence of these pathways, cells use classical NHEJ, which leads to chromosomal 
anomalies, genomic instability, and ultimately cell death [84].  
This treatment may be effective also in patients with mesothelioma carrying a germline mutation in 
BRCA1 or 2, BAP1 or possibly other genes affecting HHR (Figure 2B). 
In particular, PARPi can be effective in cells that have lost both BAP1 alleles either because of a 
germline and somatic variants (like in patients with a genetic predisposition) or because of two 
somatic variants (like in patients with sporadic cancer). However, while it is difficult to identify the 
amount of cancer subclones that harbor a biallelic variant, tumors arising in patients with a germline 
variant in a tumor suppressor gene have a very high likelihood of a second somatic variant on the 
wild-type allele. Thus, MPM that occurs in patients with a germline variant in BAP1 could 
theoretically respond to this treatment. The use of PARPi to treat the MPM patients with BAP1 loss 
has been proposed [85], and preventive screening of DNA repair genes might identify a wider group 
of patients that could benefit of such treatment, i.e. those with a defective HHR. 
Another possible treatment that was suggested for patients with BAP1 loss is the use of EZH2 
inhibitors [84]. This approach is supported by the observation that BAP1 inactivation induces 
global methylation mediated by the activation of the Polycomb repressive complex 2 (PRC2). The 
inhibition of EZH2, that encodes for the PRC2 catalytic subunit, has shown excellent results in 
mesothelioma, both in vitro and in vivo experiments [86]. 
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5. Conclusions 
Recent studies have identified germline variants in DNA repair genes in MPM patients. Although 
papers published more than ten years ago suspected that DNA repair genes played a role in MPM, 
two issues have hampered the identification of genetic factors with an unequivocal role in cancer 
development. First, past works focused on frequent variants that needed a very large panel of MPM 
patients and controls, but enrollment was difficult due to the rarity of the disease. Moreover, an 
accurate assessment of asbestos exposure was also needed, but this exposure is not routinely 
assessed with sufficient detail in clinical centers.  
Second, analyses focused on the identification of rare variants were more difficult in the past, 
because high-throughput technologies (e.g. NGS) were not yet available. One example of a variant 
analyzed in the past is a missense variant in XRCC1 [20]. XRCC1 and PARP1 are proteins involved 
in the BER pathway. It is likely that patients with variants in XRCC1 may not only be less efficient 
in correcting DNA lesions caused by asbestos exposure, but also more sensitive to PARPi. These or 
other frequent variants may also modulate the risk in patients with a truncating inherited variant in 
DNA repair genes. 
Finally, MM is an aggressive tumor that does not respond to current treatments. Development of 
new treatments is needed [85,87]. Patients with truncating mutations in HHR genes may represent a 
subgroup of patients who respond to treatments that induce synthetic lethality. 
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Legends to figures 
Figure 1: Low- risk genetic factors: possible effects 
A: Low- risk factors predisposing to mesothelioma are represented by specific SNPs in the reported 
genes. A single SNP confers a very low risk, but interaction among different SNPs may cause 
synergistic effects. B: FOXK1 (whose gene is located in a region that includes SDK1) is an 
interactor of BAP1: we speculate that the associated SNPs may modify BAP1 function and favor 
carcinogenesis. 
 
Figure 2: High- and moderate- risk genetic factors: possible role in carcinogenesis and 
treatment 
A: High- and moderate-risk factors predisposing to mesothelioma are represented by pathogenic 
truncating variants in genes involved in autosomal dominant or recessive cancer-predisposition 
syndromes. B: Their presence may favor treatments based on synthetic lethality. 
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Table 1- Low-risk genetic factors for malignant pleural mesothelioma 
Table 1a - Matullo et al. study: 407 cases vs 389 controls [23] 
Locus SNP Gene Gene Name Context Biological Process Left Gene Right Gene 
6p21 rs742109 -  
 
 
Intergenic - PRDM1 ATG5 
3q26.2 rs7632718 SLC7A14 Solute carrier family 7 
member 14 
 
Intronic Amino acid transport CLDN11 RPL22L1 
3p24.2 rs9833191 THRB Thyroid hormone receptor 
beta 
 
Intronic Transcription regulation NR1D2 MIR4792 
5q23.1 rs1508805 -  
 
 
Intergenic - PRR16 FTMT 
1q25.2 rs2501618 CEP350 Centrosome-associated 
protein 350 
 
Intronic Microtubule anchoring TOR1AIP1 QSOX1 
5q35.3 rs4701085 ADAMTS2 A disintegrin and 
metalloproteinase with 
thrombospondin motifs 2 
 
Intronic Collagen degradation ZNF354C AX747985 
4q22.1 rs4290865 -  
 
 
Intergenic - FAM190A GRID2 
13q14.3 rs9536579 -  
 
 
Intergenic - OLFM5 MIR1297 
7p21.2 rs3801094 ETV1 ETS translocation variant 1 
 
Intronic Transcription regulation ARL4A DGKB 
8q24.21 rs7841347 PVT1 Pvt1 oncogene (non-protein 
coding) 
 
Intronic Cancer pathophysiology MYC TMEM75 
15q21.1 rs10519201 SHC4 SHC-transforming protein 4 Intronic Apoptotic process,   
intracellular signal 
transduction,  cell 
proliferation, regulation 
of gene expression 
EID1 SECISBP2L 
22q12.3 rs5756444 -  
 
 
Intergenic - CSF2RB2 C22orf33/ 
TEX33 
 
Table 1b – Cadby et al. study: 428 cases vs 778 controls [24] 
Locus SNP Gene Gene Name Context Biological Process Left Gene Right Gene 
11q24.1 rs17338032 CRTAM Cytotoxic and regulatory T-
cell molecule 
 
Intronic Adaptive immune 
response 
UBASH3B JHY 
2p12 rs11126513 -  
 
 
Intergenic - C2orf3 LRRTM4 
5q13 rs1379270 RASGRF2 Ras-specific guanine 
nucleotide-releasing factor 
2 
Intronic Apoptotic process, 
regulation of Rho 
protein signal 
transduction, 
regulation of small 
GTPase mediated signal 
transduction 
MSH3 CKMT2 
7p22.2 rs12540101 SDK1 Protein sidekick-1 
 
 
 
Intronic Cell-cell junction 
organization 
CARD11 CYP3A54P 
6q15 rs4707427 -  Intergenic - AKIRIN2 SPACA1 
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8p21.3 rs10089418 -  
 
 
Intergenic - LZTS1 LINC02153 
13q13.3 rs9548166 -  
 
 
Intergenic - LINC02334 LINC00571 
5q23.1 rs4895337 -  
 
 
Intergenic - FTMT SRFBP1 
9p21.1 rs13287752 -  
 
 
Intergenic - MIR873 C9orf72 
4q12 rs282718 -  
 
 
Intergenic - IGFBP7 LINC02380 
7p22.2 rs12701229 SDK1 Protein sidekick-1 
 
 
Intronic Cell-cell junction 
organization 
CARD11 CYP3A54P 
 
Table 2 - High- and moderate -risk genetic factors for malignant pleural mesothelioma 
Reference Gene MIM # Function Tumors 
Autosomal Dominant  
Syndrome 
Autosomal Recessive 
Syndrome 
[30–33,35–
50,62] 
BAP1 603089 DNA repair 
(HRR) 
Mesothelioma 
Cutaneous melanoma  
Uveal melanoma  
Renal cell carcinoma 
Basal cell carcinoma 
Melanocytic BAP1-mutated atypical 
intradermal tumors (MBAITs) 
 
BAP1-Tumor Predisposition 
Syndrome (BAP1-TPDS) 
- 
[79,62] BRCA1 
(FANCS) 
 
113605 
 
 
 
DNA repair  
(HRR) 
Breast cancer 
Ovarian cancer 
Prostate cancer 
Pancreatic cancer 
Melanoma 
 
Hereditary Breast and 
Ovarian Cancer (HBOC) 
Fanconi anemia 
[79,62] BRCA2 
(FANCD1) 
600185 DNA repair  
(HRR) 
Breast cancer 
Ovarian cancer 
Prostate cancer 
Pancreatic cancer 
Melanoma 
 
Hereditary Breast and 
Ovarian Cancer (HBOC) 
Fanconi anemia 
[79] XPC 613208 DNA repair 
(NER) 
Basal cell carcinoma 
Squamous cell carcinoma  
Melanoma 
 
- Xeroderma 
pigmentosum (XP) 
[88,62] CDKN2A 600160 Cell cycle 
control 
Melanoma 
Pancreatic cancer 
 
Familial Atypical Multiple 
Mole Melanoma-Pancreatic 
Carcinoma Syndrome 
(FAMMPC)  
- 
[79] PALB2 
(FANCN) 
610355 DNA repair 
(HRR) 
Breast cancer 
Pancreatic cancer 
 
- Fanconi anemia 
[79] PMS1 600258 DNA repair 
(MMR) 
- 
 
 
- - 
[79] FANCC 613899 DNA repair 
(HRR) 
Head and neck squamous cell carcinoma  
Pancreatic cancer 
 
- Fanconi anemia 
[79] FANCF 
 
603467 
 
DNA repair 
(HRR) 
Head and neck squamous cell carcinoma  
Pancreatic cancer 
- Fanconi anemia 
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[79] FANCI 611360 
 
DNA repair 
(HRR) 
Head and neck squamous cell carcinoma  
Pancreatic cancer 
 
- Fanconi anemia 
[79] SLX4 
(FANCP) 
613278 DNA repair 
(HRR) 
Head and neck squamous cell carcinoma  
Pancreatic cancer 
 
- Fanconi anemia 
[79,62] ATM 607585 DNA repair 
(HRR) 
 
Breast cancer 
 
Lymphoma, Leukemia * Ataxia telangiectasia 
[62] MSH6 600678 DNA repair 
(MMR) 
 
Colorectal cancer 
 
- - 
[62] MRE11A 600814 DNA repair 
(HRR) 
 
Breast cancer 
 
- Ataxia telangiectasia 
[62] TMEM127 613403 - Pheochromocytoma 
 
- - 
[62] TP53 191170 DNA repair 
(HRR) 
Breast cancer 
Ovarian cancer 
Melanoma 
Colorectal cancer 
Osteosarcoma 
Glioma 
 
Li-Fraumeni - 
[62] SDHA 600857 - Paraganglioma - 
 
- 
*Heterozygous carriers show a moderate risk for breast and gastrointestinal cancer. 
 
 
 
